FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1497443043> ?p ?o ?g. }

• W1497443043 endingPage "1547" @default.
• W1497443043 startingPage "1536" @default.
• W1497443043 abstract "Background and purpose: Tecarfarin (ATI‐5923) is a novel vitamin K epoxide reductase inhibitor that is metabolized by esterase (mainly human carboxylesterase 2) to a single major metabolite, ATI‐5900, in rats, dogs and humans. Tecarfarin is not significantly metabolized by CYP450 enzymes. The objective of this study was to test and compare the efficacy of tecarfarin with that of warfarin, when administered either intravenously or once a day orally, to produce stable anticoagulation in beagle dogs. Experimental approach: Effects on coagulation were assessed by measuring the activity levels of Factor VII and Factor X and thromboplastin‐induced coagulation times, reported as prothrombin time (PT). Key results: Continuous intravenous infusions and oral administration of tecarfarin and warfarin caused a dose‐dependent decrease in activity of Factor VII and Factor X, and associated increase in PT. Intravenous fresh frozen canine plasma or subcutaneous vitamin K 1 treatment reversed the anticoagulant effects of orally administered tecarfarin. Consistent with the inhibitory effects of amiodarone on CYP2C9, co‐administration of amiodarone significantly increased the anticoagulation effect of warfarin and plasma warfarin concentrations. In contrast, amiodarone had no effect on the anticoagulation induced by tecarfarin or tecarfarin plasma concentrations in this model. Conclusions and implications: Overall, the data presented herein indicate that tecarfarin, via a vitamin K‐dependent mechanism, causes changes in key parameters of haemostasis in beagle dogs that are consistent with effective anticoagulation. Compared to warfarin it has a decreased potential to interact metabolically with drugs that inhibit CYP450 enzymes and, therefore, may offer an improved safety profile for patients." @default.
• W1497443043 created "2016-06-24" @default.
• W1497443043 creator A5009227603 @default.
• W1497443043 creator A5016690121 @default.
• W1497443043 creator A5020961177 @default.
• W1497443043 creator A5023735102 @default.
• W1497443043 creator A5024550793 @default.
• W1497443043 creator A5028471747 @default.
• W1497443043 creator A5034578133 @default.
• W1497443043 creator A5052048145 @default.
• W1497443043 creator A5054450533 @default.
• W1497443043 creator A5056073520 @default.
• W1497443043 creator A5071602290 @default.
• W1497443043 creator A5077379012 @default.
• W1497443043 date "2009-10-28" @default.
• W1497443043 modified "2023-10-18" @default.
• W1497443043 title "Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs" @default.
• W1497443043 cites W1980040441 @default.
• W1497443043 cites W1992223424 @default.
• W1497443043 cites W1994141234 @default.
• W1497443043 cites W2001169909 @default.
• W1497443043 cites W2006056499 @default.
• W1497443043 cites W2018747988 @default.
• W1497443043 cites W2034633980 @default.
• W1497443043 cites W2043674997 @default.
• W1497443043 cites W2064155908 @default.
• W1497443043 cites W2084868493 @default.
• W1497443043 cites W2111347580 @default.
• W1497443043 cites W2155449544 @default.
• W1497443043 cites W2156687558 @default.
• W1497443043 cites W2164327527 @default.
• W1497443043 cites W4297754350 @default.
• W1497443043 doi "https://doi.org/10.1111/j.1476-5381.2009.00420.x" @default.
• W1497443043 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2795220" @default.
• W1497443043 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19845677" @default.
• W1497443043 hasPublicationYear "2009" @default.
• W1497443043 type Work @default.
• W1497443043 sameAs 1497443043 @default.
• W1497443043 citedByCount "20" @default.
• W1497443043 countsByYear W14974430432012 @default.
• W1497443043 countsByYear W14974430432013 @default.
• W1497443043 countsByYear W14974430432014 @default.
• W1497443043 countsByYear W14974430432017 @default.
• W1497443043 countsByYear W14974430432019 @default.
• W1497443043 countsByYear W14974430432023 @default.
• W1497443043 crossrefType "journal-article" @default.
• W1497443043 hasAuthorship W1497443043A5009227603 @default.
• W1497443043 hasAuthorship W1497443043A5016690121 @default.
• W1497443043 hasAuthorship W1497443043A5020961177 @default.
• W1497443043 hasAuthorship W1497443043A5023735102 @default.
• W1497443043 hasAuthorship W1497443043A5024550793 @default.
• W1497443043 hasAuthorship W1497443043A5028471747 @default.
• W1497443043 hasAuthorship W1497443043A5034578133 @default.
• W1497443043 hasAuthorship W1497443043A5052048145 @default.
• W1497443043 hasAuthorship W1497443043A5054450533 @default.
• W1497443043 hasAuthorship W1497443043A5056073520 @default.
• W1497443043 hasAuthorship W1497443043A5071602290 @default.
• W1497443043 hasAuthorship W1497443043A5077379012 @default.
• W1497443043 hasBestOaLocation W14974430432 @default.
• W1497443043 hasConcept C112705442 @default.
• W1497443043 hasConcept C126322002 @default.
• W1497443043 hasConcept C185592680 @default.
• W1497443043 hasConcept C2776301958 @default.
• W1497443043 hasConcept C2776765323 @default.
• W1497443043 hasConcept C2776820430 @default.
• W1497443043 hasConcept C2776940978 @default.
• W1497443043 hasConcept C2777292125 @default.
• W1497443043 hasConcept C2777444498 @default.
• W1497443043 hasConcept C2777477808 @default.
• W1497443043 hasConcept C2778382381 @default.
• W1497443043 hasConcept C2779161974 @default.
• W1497443043 hasConcept C2780434524 @default.
• W1497443043 hasConcept C2780930249 @default.
• W1497443043 hasConcept C3946865 @default.
• W1497443043 hasConcept C526171541 @default.
• W1497443043 hasConcept C62231903 @default.
• W1497443043 hasConcept C71924100 @default.
• W1497443043 hasConcept C89560881 @default.
• W1497443043 hasConcept C98274493 @default.
• W1497443043 hasConceptScore W1497443043C112705442 @default.
• W1497443043 hasConceptScore W1497443043C126322002 @default.
• W1497443043 hasConceptScore W1497443043C185592680 @default.
• W1497443043 hasConceptScore W1497443043C2776301958 @default.
• W1497443043 hasConceptScore W1497443043C2776765323 @default.
• W1497443043 hasConceptScore W1497443043C2776820430 @default.
• W1497443043 hasConceptScore W1497443043C2776940978 @default.
• W1497443043 hasConceptScore W1497443043C2777292125 @default.
• W1497443043 hasConceptScore W1497443043C2777444498 @default.
• W1497443043 hasConceptScore W1497443043C2777477808 @default.
• W1497443043 hasConceptScore W1497443043C2778382381 @default.
• W1497443043 hasConceptScore W1497443043C2779161974 @default.
• W1497443043 hasConceptScore W1497443043C2780434524 @default.
• W1497443043 hasConceptScore W1497443043C2780930249 @default.
• W1497443043 hasConceptScore W1497443043C3946865 @default.
• W1497443043 hasConceptScore W1497443043C526171541 @default.
• W1497443043 hasConceptScore W1497443043C62231903 @default.
• W1497443043 hasConceptScore W1497443043C71924100 @default.
• W1497443043 hasConceptScore W1497443043C89560881 @default.

• next